Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...

Ohio is one of many states experiencing a quad-demic of infections. These 4 viral infections are COVID-19, influenza (flu), ...

HONG KONG SAR – Media OutReach Newswire – 5 February 2025 – AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory ...

Located in the United States, Europe and Australia, the advisors extend Vaxxas’ global expertise as it expands and progresses its product pipeline, including advancing the company’s COVID-19, ...

Given the important role of adjuvants in prophylactic ... In Europe, MF59 and AS03 (GlaxoSmithKline, oil-in-water emulsions) are licensed for adjuvanted influenza vaccines and AS04, a combination ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...

Add videos to your saved list and come back to them any time.

Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...

His roles included serving as Senior Vice President, Vaccine Research and Development, for Pfizer Inc ... and Head of Global Adjuvant Centre for Vaccine Development at GSK Biologicals.

Even as GSK’s RSV vaccine launch hits a serious slowdown ... Miels explained. On Tuesday, Pfizer also reported $198 million in fourth-quarter sales for its RSV shot Abrysvo.

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both companies ...